Yingchun Li

Title: Yingchun Li: Innovator in Pharmaceutical Antibody Formulations

Introduction

Yingchun Li is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceutical compositions, particularly focusing on humanized monoclonal antibodies. His work is essential in advancing therapeutic options for various medical conditions.

Latest Patents

Yingchun Li holds a patent for a pharmaceutical composition of a humanized monoclonal anti-PD-L1 antibody. This invention is crucial in the realm of antibody formulations. The composition includes 1-150 mg/ml of the humanized monoclonal anti-PD-L1 antibody, a buffer at 3-50 mM, 2-150 mg/ml of an isotonic adjuster/stabilizer, and 0.01-0.8 mg/ml of a surfactant, with a pH of about 4.5-6.8. This formulation effectively prevents the increase of antibody aggregates while maintaining the biological binding activity of the antibody over an extended period.

Career Highlights

Throughout his career, Yingchun Li has worked with prominent companies in the pharmaceutical industry. He has been associated with Nanjing Shunxin Pharmaceutical Co., Ltd. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Yingchun Li has collaborated with notable colleagues, including Jianwen Li and Yanju Cheng. These partnerships have facilitated the exchange of ideas and advancements in the field of antibody formulations.

Conclusion

Yingchun Li's contributions to the development of humanized monoclonal antibodies represent a significant advancement in pharmaceutical science. His innovative work continues to impact the medical field positively.